U.S. market Closed. Opens in 12 hours 20 minutes

KDNY | Chinook Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range N/A - N/A
52 Week Range N/A - N/A
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume N/A
Average Volume N/A
Shares Outstanding N/A
Market Cap N/A
Sector Healthcare
Industry Biotechnology
IPO Date 2020-10-06
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS N/A
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 214
Country USA
Website KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
KDNY's peers: ASND, VRCA
*Chart delayed
Analyzing fundamentals for KDNY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see KDNY Fundamentals page.

Watching at KDNY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on KDNY Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙